http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101417152-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-602 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-432 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-416 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-425 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-915 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 |
| filingDate | 2008-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-101417152-B |
| titleOfInvention | Local vascular delivery of mTOR inhibitors in combination with peroxisome proliferator-activated receptor stimulators |
| abstract | Medical devices, particularly implantable medical devices, can be coated to minimize or substantially eliminate the bioorganic reactions of the organism in which the medical device intervenes. The medical device can be coated with any number of biocompatible substances. A therapeutic drug, agent or compound may be mixed with a biocompatible substance and attached to at least a portion of the medical device. These therapeutic agents or compounds can further reduce the bioorganic response of the organism in which the medical device intervenes. In addition, these therapeutic drugs, agents and/or compounds can be used to promote healing, including the prevention of thrombosis. These therapeutic drugs, agents and/or compounds may also be used in the treatment of certain diseases, including vulnerable plaque and atherosclerosis in type II diabetic patients. Therapeutic agents can also be delivered to localized areas of the lesion. In topical delivery, liquid formulations would be expected to increase the potency and delivery of a particular drug. Also, the device can be adjusted to facilitate endothelialization. Various materials of matter and methods of envelope manipulation can be used to retain agents and compounds on the medical device until their release and installation. Additionally, the means for releasing the implantable medical device can be adjusted to reduce the likelihood of damage to the implantable medical device during deployment. Furthermore, combinations of various polymers can be used to control the rate of elution of therapeutic drugs, agents and/or compounds from implantable medical devices. |
| priorityDate | 2007-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 627.